141 related articles for article (PubMed ID: 38215660)
1. Spatiotemporal modeling of radiopharmaceutical transport in solid tumors: Application to
Piranfar A; Soltani M; Kashkooli FM; Uribe CF; Rahmim A
Comput Methods Programs Biomed; 2024 Mar; 245():108004. PubMed ID: 38215660
[TBL] [Abstract][Full Text] [Related]
2. Radiopharmaceutical transport in solid tumors via a 3-dimensional image-based spatiotemporal model.
Piranfar A; Moradi Kashkooli F; Zhan W; Bhandari A; Saboury B; Rahmim A; Soltani M
NPJ Syst Biol Appl; 2024 Apr; 10(1):39. PubMed ID: 38609421
[TBL] [Abstract][Full Text] [Related]
3. Localized radiotherapy of solid tumors using radiopharmaceutical loaded implantable system: insights from a mathematical model.
Piranfar A; Souri M; Rahmim A; Soltani M
Front Oncol; 2024; 14():1320371. PubMed ID: 38559559
[TBL] [Abstract][Full Text] [Related]
4. Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors.
Wang Z; Tian R; Niu G; Ma Y; Lang L; Szajek LP; Kiesewetter DO; Jacobson O; Chen X
Bioconjug Chem; 2018 Sep; 29(9):3213-3221. PubMed ID: 30105912
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Development in Radiopharmaceutical Therapy for Prostate Cancer.
Alati S; Singh R; Pomper MG; Rowe SP; Banerjee SR
Semin Nucl Med; 2023 Sep; 53(5):663-686. PubMed ID: 37468417
[TBL] [Abstract][Full Text] [Related]
6. Albumin-Binding and Conventional PSMA Ligands in Combination with
Tschan VJ; Busslinger SD; Bernhardt P; Grundler PV; Zeevaart JR; Köster U; van der Meulen NP; Schibli R; Müller C
J Nucl Med; 2023 Oct; 64(10):1625-1631. PubMed ID: 37442604
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
[TBL] [Abstract][Full Text] [Related]
8. Enhancing Treatment Efficacy of
Kuo HT; Merkens H; Zhang Z; Uribe CF; Lau J; Zhang C; Colpo N; Lin KS; Bénard F
Mol Pharm; 2018 Nov; 15(11):5183-5191. PubMed ID: 30251544
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Study of Therapeutic Efficacy of a New Russian Radiopharmaceutical
Tishchenko VK; Vlasova OP; Lebedeva AA; Fedorova AV; Pankratov AA; Morozova NB; Kuzenkova KA; Stepchenkova ED; Shegai PV; Ivanov SA; Kaprin AD
Bull Exp Biol Med; 2023 Dec; 176(2):224-226. PubMed ID: 38191882
[TBL] [Abstract][Full Text] [Related]
10. An Improved
Mease RC; Kang CM; Kumar V; Banerjee SR; Minn I; Brummet M; Gabrielson KL; Feng Y; Park A; Kiess AP; Sgouros G; Vaidyanathan G; Zalutsky MR; Pomper MG
J Nucl Med; 2022 Feb; 63(2):259-267. PubMed ID: 34088772
[TBL] [Abstract][Full Text] [Related]
11. Preclinical dosimetric studies of
Meléndez-Alafort L; Ferro-Flores G; Santos-Cuevas C; Ocampo-García B; Turato S; Fracasso G; Bolzati C; Rosato A; De Nardo L
Med Phys; 2021 Jul; 48(7):4064-4074. PubMed ID: 33966284
[TBL] [Abstract][Full Text] [Related]
12. Establishing
Fendler WP; Stuparu AD; Evans-Axelsson S; Lückerath K; Wei L; Kim W; Poddar S; Said J; Radu CG; Eiber M; Czernin J; Slavik R; Herrmann K
J Nucl Med; 2017 Nov; 58(11):1786-1792. PubMed ID: 28546332
[TBL] [Abstract][Full Text] [Related]
13. Clinical translation of (177)Lu-labeled PSMA-617: Initial experience in prostate cancer patients.
Das T; Guleria M; Parab A; Kale C; Shah H; Sarma HD; Lele VR; Banerjee S
Nucl Med Biol; 2016 May; 43(5):296-302. PubMed ID: 27150032
[TBL] [Abstract][Full Text] [Related]
14. Toward Single-Time-Point Image-Based Dosimetry of
Brosch-Lenz J; Delker A; Völter F; Unterrainer LM; Kaiser L; Bartenstein P; Ziegler S; Rahmim A; Uribe C; Böning G
J Nucl Med; 2023 May; 64(5):767-774. PubMed ID: 36657980
[TBL] [Abstract][Full Text] [Related]
15. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
16. Examining Absorbed Doses of Indigenously Developed
Kamaldeep ; Wanage G; Sahu SK; Maletha P; Adnan A; Suman S; Basu S; Das T; Banerjee S
Cancer Biother Radiopharm; 2021 Apr; 36(3):292-304. PubMed ID: 32379495
[No Abstract] [Full Text] [Related]
17.
Banerjee SR; Kumar V; Lisok A; Chen J; Minn I; Brummet M; Boinapally S; Cole M; Ngen E; Wharram B; Brayton C; Hobbs RF; Pomper MG
Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2545-2557. PubMed ID: 31399803
[TBL] [Abstract][Full Text] [Related]
18. Radiation Dosimetry for
Okamoto S; Thieme A; Allmann J; D'Alessandria C; Maurer T; Retz M; Tauber R; Heck MM; Wester HJ; Tamaki N; Fendler WP; Herrmann K; Pfob CH; Scheidhauer K; Schwaiger M; Ziegler S; Eiber M
J Nucl Med; 2017 Mar; 58(3):445-450. PubMed ID: 27660138
[TBL] [Abstract][Full Text] [Related]
19. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer.
Kabasakal L; AbuQbeitah M; Aygün A; Yeyin N; Ocak M; Demirci E; Toklu T
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1976-83. PubMed ID: 26227531
[TBL] [Abstract][Full Text] [Related]
20. Prostate-Specific Membrane Antigen Radioligand Therapy Using
Schuchardt C; Zhang J; Kulkarni HR; Chen X; Müller D; Baum RP
J Nucl Med; 2022 Aug; 63(8):1199-1207. PubMed ID: 34887335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
